MetaVia

MetaVia P/B

The P/B (Price-to-Book Ratio) of MetaVia (MTVA) as of Oct 30, 2026 is 1.02. In the previous year, P/B (Price-to-Book Ratio) was 0.69 — a change of 48.72% (higher).

P/B

1.02

YoY

48.72%

Last updated:

P/B (Price-to-Book Ratio) of MetaVia is 2025 1.02 . P/B (Price-to-Book Ratio) of MetaVia was 2024 0.69 . It decreases by 48.72% higher compared to the previous year.

The MetaVia P/B history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/B
Date
P/B
Jan 1, 2018
-0.41 USD
Jan 1, 2019
0.44 USD
Jan 1, 2020
0.75 USD
Jan 1, 2021
0.37 USD
Jan 1, 2022
0.25 USD
Jan 1, 2023
0.33 USD
Jan 1, 2024
0.69 USD
Jan 1, 2025
1.02 USD
The MetaVia P/B history
YEARP/BYoY
1.02+48.72%
0.69+110.38%
0.33+30.36%
0.25-32.89%
0.37-50.65%
0.75+70.65%
0.44-208.09%
-0.41-129.66%
1.38+423.52%
0.26-160.00%
-0.44-95.71%
-10.24—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

MetaVia Stock analysis

What does MetaVia do? NeuroBo Pharmaceuticals, Inc. generates revenue by developing novel pharmaceuticals to address unmet medical needs in patients suffering from neurodegenerative disorders. The company focuses on specific therapeutic areas including Painful Diabetic Neuropathy (PDN) and Alzheimer’s disease, targeting these conditions with its proprietary product candidates. This strategy allows the firm to serve the clinical-stage biotechnology market by offering specialized treatments for serious health conditions. The company’s product portfolio includes NB-01, which is designed to target neuropathic pain with an indication for PDN, and NB-02, a drug developed for Alzheimer’s and tauopathies. Additionally, the firm offers Gemcabene, a therapy focused on treating dyslipidemia, a condition that increases the risk of life-threatening cardiovascular disease. Gemcabene is specifically directed at orphan indications such as homozygous familial hypercholesterolemia (HoFH) and severe hypertriglyceridemia (SHTG). Furthermore, NeuroBo Pharmaceuticals, Inc. is developing a capsule formulation of niclosamide for coronavirus indications. By expanding its research into these diverse medical conditions, the company aims to provide comprehensive pharmaceutical solutions. The firm operates from its headquarters in Boston, Massachusetts, and maintains a focused development pipeline to bring these treatments to market. MetaVia is one of the most popular companies on Eulerpool.

Frequently Asked Questions about MetaVia stock

P/B (Price-to-Book Ratio) of MetaVia is 1.02 in 2025.

P/B (Price-to-Book Ratio) of MetaVia changed from 0.69 to 1.02, representing a 48.72% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of P/B (Price-to-Book Ratio) MetaVia since 2006 – with annual values, charts, and detailed analysis.

The Price-to-Book ratio compares a company's market price to its book value. A low P/B may indicate an undervalued stock, while a high P/B could suggest overvaluation or strong growth expectations.

P/B = Stock Price / Book Value per Share

To evaluate P/B (Price-to-Book Ratio)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for P/B (Price-to-Book Ratio).

A 'good' varies by industry and company stage. On Eulerpool, you can compare P/B (Price-to-Book Ratio)'s MetaVia with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — MetaVia

All Key Metrics — MetaVia